The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1742
ISSUE1742
November 24, 2025
Noninsulin Drugs for Type 2 Diabetes
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Noninsulin Drugs for Type 2 Diabetes
November 24, 2025 (Issue: 1742)
Diet, exercise, and weight loss can improve glycemic
control, but most patients with type 2 diabetes
eventually require glucose-lowering pharmacotherapy.
An A1C goal of...more
- American Diabetes Association Professional Practice Committee. Introduction and methodology: standards of care in diabetes – 2025. Diabetes Care 2025; 48(Suppl. 1):S1. doi:10.2337/dc25-SINT
- M Bahardoust et al. Effect of metformin (vs. placebo or sulfonylurea) on all-cause and cardiovascular mortality and incident cardiovascular events in patients with diabetes: an umbrella review of systematic reviews with meta-analysis. J Diabetes Metab Disord 2024; 23:27. doi:10.1007/s40200-023-01309-y
- FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. April 2017. Available at: https://bit.ly/3SdEFRN. Accessed November 6, 2025.
- B Neal et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377:644. doi:10.1056/nejmoa1611925
- B Zinman et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:2117. doi:10.1056/nejmoa1504720
- V Perkovic et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:2295. doi:10.1056/nejmoa1811744
- SD Wiviott et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380:347. doi:10.1056/nejmoa1812389
- SD Solomon et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022; 387:1089. doi:10.1056/nejmoa2206286
- HJL Heerspink et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383:1436. doi:10.1056/nejmoa2024816
- M Packer et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383:1413. doi:10.1056/nejmoa2022190
- The EMPA-KIDNEY Collaborative Group. Long-term effects of empagliflozin in patients with chronic kidney disease. N Engl J Med 2025; 392:777. doi:10.1056/nejmoa2409183
- CP Cannon et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020; 383:1425. doi:10.1056/nejmoa2004967
- Bexagliflozin (Brenzavvy) – a fifth SGLT2 inhibitor for type 2 diabetes. Med Lett Drugs Ther 2023; 65:130.
- MN Kosiborod et al. Semaglutide in patients with obesityrelated heart failure and type 2 diabetes. N Engl J Med 2024; 390:1394. doi:10.1056/nejmoa2313917
- HC Gerstein et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394:121. doi:10.1016/s0140-6736(19)31149-3
- HC Gerstein et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 2019; 394:131. doi:10.1016/s0140-6736(19)31150-x
- SP Marso et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375:311. doi:10.1056/nejmoa1603827
- JFE Mann et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377:839. doi:10.1056/nejmoa1616011
- SP Marso et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375:1834. doi:10.1056/nejmoa1607141
- Semaglutide (Ozempic) – another injectable GLP-1 receptor agonist for type 2 diabetes. Med Lett Drugs Ther 2018; 60:19.
- V Perkovic et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024; 391:109. doi:10.1056/nejmoa2403347
- DK McGuire et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med 2025; 392:2001. doi:10.1056/nejmoa2501006
- MP Bonaca et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet 2025; 405:1580. doi:10.1016/s0140-6736(25)00509-4
- A new indication for semaglutide (Wegovy). Med Lett Drugs Ther 2024; 66:66.
- Semaglutide (Wegovy) for MASH. Med Lett Drugs Ther 2025; 67:161.
- Tirzepatide (Mounjaro) for type 2 diabetes. Med Lett Drugs Ther 2022; 64:105.
- SJ Nicholls et al. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart J 2024; 267:1. doi:10.1016/j.ahj.2023.09.007
- Tirzepatide (Zepbound) for chronic weight management. Med Lett Drugs Ther 2023; 65:205.
- Tirzepatide (Zepbound) for obstructive sleep apnea. Med Lett Drugs Ther 2025; 67:29.
- H Yao et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ 2024; 384:e076410. doi:10.1136/bmj-2023-076410
- T Karagiannis et al. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia 2024; 67:1206. doi:10.1007/s00125-024-06144-1
- W Scott Butsch et al. Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: a retrospective observational study. Obes Pillars 2025; 15:100186. doi:10.1016/j.obpill.2025.100186
- Y Noh et al. Glucagon-like peptide-1 receptor agonists and risk for gastroesophageal reflux disease in patients with type 2 diabetes: a population-based cohort study. Ann Intern Med 2025; 178:1268. doi:10.7326/annals-24-03420
- In brief: GI effects of GLP-1 receptor agonists. Med Lett Drugs Ther 2023; 65:191.
- In brief: New FDA warning on pulmonary aspiration with GLP-1 receptor agonists. Med Lett Drugs Ther 2024; 66:201.
- American Diabetes Association Professional Practice Committee. 12. Retinopathy, neuropathy, and foot care: standards of care in diabetes-2025. Diabetes Care 2025; 48(Suppl 1):S252. doi:10.2337/dc25-S012
- CX Cai et al. Semaglutide and nonarteritic anterior ischemic optic neuropathy. JAMA Ophthalmol 2025; 143:304. doi:10.1001/jamaophthalmol.2024.6555
- J Rosenstock et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 2019; 321:69. doi:10.1001/jama.2018.18269
- R Shor et al. Glucagon-like peptide-1 receptor agonists and risk of neovascular age-related macular degeneration. JAMA Ophthalmol 2025; 143:587. doi:10.1001/jamaophthalmol.2025.1455
- KB Filion et al. Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: a population-based cohort study. Br J Clin Pharmacol 2019; 85:2378. doi:10.1111/bcp.14056
- A Douros et al. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population-based cohort study. BMJ 2018; 362:k2693. doi:10.1136/bmj.k2693
- AV Hernandez et al. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 2011; 11:115. doi:10.2165/11587580-000000000-00000
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Noninsulin Drugs for Type 2 Diabetes
Article code: 1742a
Article code: 1742a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.